Myricanol 是一种具有多种生物活性的二芳基庚烷类化合物和 Nampt 激活剂,可通过增加 Sirtuin 1 (SIRT1)、PRDX5 活性并调控炎症因子发挥抗炎作用、缓解糖皮质激素诱导的肌肉萎缩,对人肺腺癌 A549 细胞具有生长抑制和凋亡 (apoptosis) 诱导作用,可促进微管相关蛋白 tau 的自噬 (autophagy) 清除以发挥神经保护作用,可抑制 PDGFRβ 和 NF-κB 信号通路以保护心血管功能,可激活线粒体转录因子 A (TFAM) 表达以发挥抗肾纤维化作用,并可激活 AMPK 改善胰岛素抵抗。
产品编号: MS-H68346 纯度: 98.93% CAS No.: 33606-81-4 分子式: C21H26O5 分子量: 358.43
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Myricanol 是一种具有多种生物活性的二芳基庚烷类化合物和 Nampt 激活剂,可通过增加 Sirtuin 1 (SIRT1)、PRDX5 活性并调控炎症因子发挥抗炎作用、缓解糖皮质激素诱导的肌肉萎缩,对人肺腺癌 A549 细胞具有生长抑制和凋亡 (apoptosis) 诱导作用,可促进微管相关蛋白 tau 的自噬 (autophagy) 清除以发挥神经保护作用,可抑制 PDGFRβ 和 NF-κB 信号通路以保护心血管功能,可激活线粒体转录因子 A (TFAM) 表达以发挥抗肾纤维化作用,并可激活 AMPK 改善胰岛素抵抗。

生物实验数据

生物活性 Myricanol is a diarylheptanoid compound with multiple biological activities and a Nampt activator that exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activity and regulating inflammatory factors, inhibits growth and induces apoptosis in human lung adenocarcinoma A549 cells, promotes autophagic clearance of microtubule-associated protein tau to exert neuroprotective effects, inhibits PDGFRβ and NF-κB signaling pathways to protect cardiovascular function, activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects, and activates AMPK to improve insulin resistance.
IC50 & Target

SIRT1

 

NF-κB

 

AMPK

 

PDGFRβ

 

体外研究
(In Vitro)

Myricanol (0.01-150 μM,1-72 小时) 可通过激活自噬有效降低 HEK293T 细胞 (IC50 约为 18.56 μM) 和小鼠急性离体脑组织 (100 和 150 μM) 中的 tau 水平。
Myricanol (0-10 μM,24 小时) 显著逆转地塞米松 (DEX) (MS-E10819) 引起的线粒体含量减少和功能障碍,并通过激活 sirtuin 1 促进自噬、抑制细胞凋亡,从而保护 C2C12 肌管。
Myricanol (1.25-5 μmol/L,24 小时) 可减少经棕榈酸 (PA) (MS-A29753) 处理的 C2C12 肌管中的脂质积累,增强线粒体功能,保护 C2C12 肌管免受胰岛素抵抗的影响,并增加 C2C12 肌管中鸢尾素的产生和分泌,进而诱导脂肪细胞褐变。
Myricanol (5-20 μM) 通过增强 TFAM 来抑制肾脏纤维化,改善 ZNRF1 和 LCN2 之间的相互作用,并加剧 TGF-β1 诱导的 HK2 细胞中的铁死亡。
MY (2.5-10 μM) 可保护 C2C12 肌管免受叔丁基过氧化氢 (TBHP) 造成的氧化损伤,并通过靶向 PRDX5 来改善线粒体的生物合成和功能。
Myricanol (3-30 μM, 24.5 小时) 通过抑制血小板衍生生长因子受体通路的激活和 NF-κB p65 易位来抑制血小板衍生生长因子-BB 诱导的血管平滑肌细胞增殖和迁移。
Myricanol (5-40 μM, 24 小时) 靶向 C2C12 细胞中的 Nampt,后者参与胰岛素增敏作用。
Myricanol (1.56-50 μg/mL,48 小时-10 天) 可抑制 A549 细胞增殖 (IC50 = 4.85 μg/mL) 和克隆形成并诱导细胞凋亡。

Western Blot Analysis

Cell Line: HEK293T cells
Concentration: 18 μM
Incubation Time: 1, 6, 24, 48, 72 h
Result: Completely be blocked the tau-lowering effect by 3-MA (MS-H80278).
Increased the LC3β-II/I ratio.

Western Blot Analysis

Cell Line: C2C12 myotubes stimulated by with DEX
Concentration: 0, 0.25, 5, 10 μM
Incubation Time: 24 h
Result: Restored the expression of myosin heavy chain (MyHC), muscle atrophy F-box protein (atrogin-1), and muscle ring-finger protein 1 (MuRF1).
Dose-dependent upregulated SIRT1 expression.
Restored the phosphorylation of Akt and FoxO3a that is inhibited by DEX.
Increased the expression levels of Cox2, Tom20, UCP3, and PGC-1α.
Reversed DEX-induced increases of total and acetylated FoxO3a levels, which were abolished by co-treatment of EX-527 (MS-R66059).
Inhibited expression of apoptosis-associated proteins Bax, cleaved caspase-3 and Increased Bcl-2.

Western Blot Analysis

Cell Line: C2C12 myotubes stimulated by with PA
Concentration: 1.25, 2.5, and 5 μmol/L
Incubation Time: 24 h
Result: Activated the AMPK/ACC signaling pathway and upregulated the expression of PGC-1α.
Activated of the insulin signaling pathway (IRS-1/Akt/GSK-3β).
Promoted the production and secretion of FNDC5/irisin.
Decreased the lipid accumulation in 3T3‐L1 adipocytes in a dose-dependent manner.
Increased the browning markers, PGC‐1α and UCP1, and the mitochondrial marker, COX2, and Suppressed the adipogenic marker, PPARγ, in 3T3‐L1 adipocytes, dose-dependently.

Cell Migration Assay

Cell Line: Primary VSMCs
Concentration: 3, 10 and 30 μM
Incubation Time: Pretreated 30 min and treated with PDGF-BB for 24 h
Result: Partially suppressed the migration at 10 and 30 μM.

Western Blot Analysis

Cell Line: Primary VSMCs
Concentration: 3, 10 and 30 μM
Incubation Time: Pretreated 30 min and treated with PDGF-BB for 24 h
Result: Reduced PCNA, E2F1 and p-Rb.
Reduced Cyclin D1, Cyclin E1 and recovered p53.
Inhibited MM2 and MM9.
Inhibited PDGFRβ pathway and MAPK pathway.
Significantly inhibited p65 nuclear accumulation.

Cell Proliferation Assay

Cell Line: A549 cells
Concentration: 1.56, 3.125, 6.25, 12.5, 25 and 50 μg/mL
Incubation Time: 48 h
Result: Inhibited cell proliferation in a concentration-dependent manner.

Apoptosis Analysis

Cell Line: A549 cells
Concentration: 5 μg/mL
Incubation Time: 48 h
Result: Increased the apoptosis rate from 4.13% to 34.3%, and the proportion of early apoptosis increased significantly.
Upregulated Caspase-3, Caspase-9, Bax and p21, downregulated Bcl-2.
体内研究
(In Vivo)

Myricanol (5-50 mg/kg,腹腔注射,每日一次,连续 10 天) 可通过激活 SIRT1 来预防地塞米松引起的小鼠肌肉萎缩和无力。
Myricanol (0.5-2.5 mg/mL,溶于PEG 400 (MS-Z56816) 溶液中,腹腔注射,每日一次,连续 18 周) 可延缓高脂饮食 (HFD) 小鼠的脂肪质量增长、改善血脂状况并提高其胰岛素敏感性。
Myricanol (0.5-2 mg/mL,腹腔注射,每日一次,连续 1 周) 可有效改善慢性肾病 (CKD) 小鼠的肾功能并抑制纤维化。
Myricanol (10-50 mg/kg,腹腔注射,每日一次,连续 20 天) 可通过减轻线粒体的氧化损伤来保护老年小鼠免于肌肉萎缩,并确定直接的蛋白质靶点及其潜在机制。
Myricanol (5 mg/kg,腹腔注射,每日一次,连续 14 天) 可显著减少颈动脉结扎引起的内膜增生。

Animal Model: DEX-induced muscle dysfunction established in male C57BL/6 mice (8-10 weeks old)
Dosage: 5 and 50 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 10 days
Result: Reduced the loss of muscle mass.
Rescued dexamethasone-induced muscle weakness, indicated by improved grip strength.
Upregulated SIRT1 and PGC-1α, reduced atrogin-1/MuRF1.
Animal Model: HFD model established in male C57BL/6 mice (8-10 weeks old)
Dosage: 0.5 and 2.5 mg/mL, dissolved in PEG 400 (MS-Z56816) solution
Administration: Intraperitoneal injection (i.p.), once daily for 18 weeks
Result: Inhibited weight gain induced by high-fat diet and reduces fat tissue accumulation.
Improved the glucose tolerance and insulin sensitivity of HFD mice (reduce the HOMA-IR index).
Reduced serum triglycerides, total cholesterol and LDL cholesterol, and increased HDL cholesterol).
Increased energy consumption (oxygen consumption).
Reduced lipid deposition in skeletal muscles and improved muscle function (as measured by grip strength test).
Activated the AMPK/PGC-1α signaling pathway in skeletal muscle.
Increased the expression of FNDC5 in skeletal muscle and the serum level of irisin.
Induced the browning of white adipose tissue in the groin region.
Animal Model: CKD model induced by unilateral ureteral obstruction (UUO) established in male C57BL/6 mice (6-8 weeks old)
Dosage: 0.5 and 2 mg/mL along with an equal volume of normal saline
Administration: Intraperitoneal injection (i.p.), once daily for one weeks
Result: Significantly reduced serum creatinine and urea nitrogen levels.
Showed a 40-60% reduction in collagen deposition.
Downregulated fibrosis markers (FN, α-SMA).
Significantly upregulated TFAM and GPX4 expressions and decreased 4-HNE.
Animal Model: Sarcopenia phenotypes model established in 18-month-old male C57BL/6J mice
Dosage: 10 and 50 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 10 days
Result: Improved grip strength in aging mice.
Significantly improved Quad, Gast and TA muscle index.
Reduced mitochondrial vacuolization and cristae structure disruption.
Animal Model: Carotid artery wire ligation injury model established in eight-week-old male C57BL/6 mice
Dosage: 5 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 14 days
Result: Showed significantly reduced intima, both the ratio of intima to media (I/M ratio) and intimal area.
Had significantly inhibited Ki67 expression and F4/80 expression.
性状 固体
颜色 White to off-white

化学信息

分子量 358.43
分子式 C21H26O5
CAS No. 33606-81-4

储存&溶解度

储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础